Radicle Science has pioneered a remarkable ability to put non-pharmaceutical products through large, rigorous clinical trials, thereby unlocking powerful new possibilities for affordable treatments.

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

The right balance between the seriousness of the disease and the excitement over advances in treatment makes this interactive, immersive experience memorable ...

Peter WT Pisters, M.D., president of The University of Texas MD Anderson Cancer Center, was honored today with the Charles M.

Post-diagnosis weight gain over ~1.5 years is consistently associated with increased breast cancer–specific and all-cause mortality across meta-analyses. How GLP-1 weight-loss drugs fit after breast ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

The evolving story of GLP-1 receptor agonists in oncology has yet another new chapter.Several studies presented at San Antonio Breast Cancer Symposium suggested the medications may help extend ...

If the rest of 2026 continues in this vein, we may look back on January and February as the moment the sector recognised that ...

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

News, features, and commentary about cancer-related issues ...

Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies. Learn why RIGL stock is a Buy.

In the 20th-century statistics wars, Bayesians were underdogs. Now their methods may help speed treatments to market.